

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (**currently amended**): A method of specifically activating cytotoxic T lymphocytes in an animal having a breast cancer neoplasm that overexpresses a Her-2/Neu protein, the method comprising the step of administering the polypeptide of SEQ ID NO:12 to said animal, thereby activating cytotoxic T lymphocytes in the animal having said neoplasm that overexpresses said Her-2/Neu.

Claims 2-60 (canceled)

Claim 61 (**currently amended**): A method of treating a patient having a breast cancer neoplasm and in need of ~~treatment of said neoplasm, wherein cells of said neoplasm overexpressing~~ a Her-2/Neu protein, the method comprising the step of administering the a polypeptide of ~~with~~ the amino acid sequence VMAGVGSPYV (SEQ ID NO:12) to the patient, thereby treating the breast cancer in the patient having said neoplasm wherein cells of said neoplasm overexpress said Her-2/Neu protein.

Claim 62 (previously presented): The method of claim 61, wherein said polypeptide is incorporated into a

pharmaceutical composition distant comprising a pharmaceutically acceptable carrier.

- Claim 63 (previously presented): The method of claim 61, wherein said polypeptide is linked to a carrier.
- Claim 64 (previously presented): The method of claim 61, wherein said polypeptide is administered to said patient as a homopolymer.
- Claim 65 (previously presented): The method of claim 61, further comprising the step of administering a second component to said patient, wherein said second component primes cytotoxic T lymphocytes (CTLs) for activation.
- Claim 66 (previously presented): The method of claim 65, wherein the second component is tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 67 (previously presented): The method of claim 61, further comprising the step of administering a second polypeptide to said animal.
- Claim 68 (previously presented): The method of claim 67, wherein the second polypeptide is TPPAYRPPNAPIL (SEQ ID NO:9).
- Claim 69 (previously presented): The method of claim 1, wherein said polypeptide is incorporated into a

pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

- Claim 70 (previously presented): The method of claim 1, wherein said polypeptide is linked to a carrier.
- Claim 71 (previously presented): The method of claim 1, wherein said polypeptide is administered to said animal as a homopolymer.
- Claim 72 (previously presented): The method of claim 1, wherein said immunizing step further comprises administering a second component to said animal, wherein said second component primes said CTLs for activation.
- Claim 73 (previously presented): The method of claim 72, wherein said second component is tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 74 (previously presented): The method of claim 1, wherein the immunizing step further comprises administering a second polypeptide to said animal.
- Claim 75 (previously presented): The method of claim 74, wherein the second polypeptide is TPPAYRPPNAPIL (SEQ ID NO:9).